Myovant Sciences (NYSE: MYOV) is one of 48 publicly-traded companies in the “Biopharmaceuticals” industry, but how does it compare to its competitors? We will compare Myovant Sciences to related companies based on the strength of its analyst recommendations, dividends, profitability, institutional ownership, valuation, risk and earnings.
Risk & Volatility
Myovant Sciences has a beta of -2.42, indicating that its share price is 342% less volatile than the S&P 500. Comparatively, Myovant Sciences’ competitors have a beta of 0.88, indicating that their average share price is 12% less volatile than the S&P 500.
This is a summary of current recommendations for Myovant Sciences and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Myovant Sciences Competitors||143||806||1782||60||2.63|
Myovant Sciences currently has a consensus target price of $22.50, indicating a potential upside of 78.01%. As a group, “Biopharmaceuticals” companies have a potential upside of 8.01%. Given Myovant Sciences’ stronger consensus rating and higher possible upside, research analysts plainly believe Myovant Sciences is more favorable than its competitors.
Earnings and Valuation
This table compares Myovant Sciences and its competitors revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Myovant Sciences||N/A||-$83.44 million||-8.96|
|Myovant Sciences Competitors||$564.12 million||$96.17 million||70.63|
Myovant Sciences’ competitors have higher revenue and earnings than Myovant Sciences. Myovant Sciences is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This table compares Myovant Sciences and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Myovant Sciences Competitors||-13,479.75%||-110.87%||-28.07%|
Insider and Institutional Ownership
79.2% of Myovant Sciences shares are owned by institutional investors. Comparatively, 43.1% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 2.8% of Myovant Sciences shares are owned by insiders. Comparatively, 15.3% of shares of all “Biopharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Myovant Sciences competitors beat Myovant Sciences on 7 of the 13 factors compared.
About Myovant Sciences
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland. Inhibition of GnRH receptors decreases the release of the gonadotropins, luteinizing hormone, or LH, and follicle-stimulating hormone, or FSH, thereby decreasing the down-stream production of estrogen and progesterone by the ovaries in women and testosterone by the testes in men. It is advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain and prostate cancer. It intends to develop its second product candidate, RVT-602, for the treatment of female infertility as part of assisted reproduction.
Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.